Demand for Wegovy and other GLP-1 drugs used to treat obesity and diabetes has skyrocketed, but a new report suggests that many people may not be sticking with their weight-loss treatment long enough.

Al-Aly and his colleagues found that people starting the GLP-1 drugs had lower risks of developing addiction to multiple substances. Compared with the other medications, people taking the GLP-1 drugs ...

The use of drugs like Ozempic, Wegovy and Zepbound in people with type 1 diabetes has risen sharply over the past decade, a new study finds, even though there’s little information on the drugs’ safety ...

A majority of people with overweight or obesity prescribed glucagon-like peptide 1 receptor agonists (GLP-1 RAs) discontinue them within 1 year, with higher quit rates among those without type 2 ...

A new report based on national prescription data shows weight-loss drug use is rising among kids and teens. GLP-1 medications, like Ozempic and Wegovy, are drugs originally developed to treat diabetes ...

The use of GLP-1 receptor agonists, and particularly liraglutide, was associated with an increased risk of developing nonarteritic anterior ischemic optic neuropathy (NAION) during the first year of ...